Zofran News and Research

RSS

Zofran is a drug used to treat nausea and vomiting caused by cancer treatment. It is a type of serotonin receptor antagonist and a type of antiemetic. Also called ondansetron hydrochloride

UCLA study shows anti-nausea drug does not increase risk of birth defects

Women suffering from extreme morning sickness often take Zofran (ondansetron) to combat their debilitating nausea and vomiting. However, two studies have found that the drug may increase risk of heart defects and cleft palate in children exposed in utero.

10 May 2016

Multi-drug therapy can benefit patients at higher risk for post-operative nausea and vomiting

Ninety-seven percent of bariatric surgery patients avoided post-operative nausea and vomiting with the addition of a second drug to the standard treatment given during surgery, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.

14 Oct 2013

Tokai raises $23M in Series D3 financing

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that it has raised $23 million in a Series D3 financing.

20 Sep 2011

Anti-nausea drug Zofran being tested for its potential heart rhythm side effects

The United States health regulators Food and Drug Administration (FDA) are looking at the safety of GlaxoSmithKline's anti-nausea drug Zofran generically known as ondansetron, to ascertain whether there is a potential risk of abnormal heart rhythm.

16 Sep 2011

Extreme morning sickness drug comes at a price

Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.

31 Jan 2011

FDA approves Lannett's ANDA for Ondansetron Injection

Lannett Company, Inc., a manufacturer of generic pharmaceuticals, announced today that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Ondansetron Injection, USP, 2 mg/mL, Single-Dose Vials. Ondansetron Injection, USP, 2 mg/mL is the generic version of GlaxoSmithKline's Zofran Injection, 2 mg/mL.

7 Aug 2010

MonoSol partner Strativa receives FDA approval for Zuplenz OSF

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in film pharmaceutical products, in collaboration with APR Applied Pharma Research s.a. of Switzerland and Labtec GmbH of Germany, today announced that its partner, Strativa Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for Zuplenz® oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

8 Jul 2010

Strativa receives FDA approval for Zuplenz oral soluble film

Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Zuplenz® (ondansetron) oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting. Zuplenz, a unique formulation of ondansetron, is the first oral soluble film approved by the FDA as a prescription medication.

3 Jul 2010

SCOLR Pharma grants RedHill worldwide rights to market and sell CDT-based ondansetron

SCOLR Pharma, Inc. today announced that it has executed a Licensing Agreement with RedHill Biopharma Ltd. an Israeli corporation, (RedHill), granting RedHill the worldwide rights to market and sell ondansetron tablet formulations based on SCOLR's proprietary extended delivery technology (CDT). Ondansetron hydrochloride is the active ingredient in Zofran®, GlaxoSmithKline's drug to prevent chemotherapy and radiation related nausea and vomiting.

6 May 2010

FDA approves Lannett's ANDA for Ondansetron Injection USP, 2 mg/mL, Multi-Dose Vials

Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Ondansetron Injection USP, 2 mg/mL, Multi-Dose Vials. Ondansetron Injection USP, 2 mg/mL is the generic equivalent of GlaxoSmithKline's Zofran® Injection, 2 mg/mL. For the 12 months ending December 2009 U.S. sales of Ondansetron Injection USP, 2 mg/mL were approximately $58 million at Average Wholesale Price (AWP). A launch date for the product has not yet been set.

20 Apr 2010

Ginger reduces post-chemotherapy nausea

People with cancer can reduce post-chemotherapy nausea by 40 percent by using ginger supplements, along with standard anti-vomiting drugs, before undergoing treatment, according to scientists at the University of Rochester Medical Center.

15 May 2009

Ondansetron helps reduce vomiting, hospital admissions in children with gastroenteritis

University of North Carolina at Chapel Hill researchers have demonstrated that a drug called ondansetron helps reduce vomiting, the need for intravenous fluids and hospital admissions in children with acute gastroenteritis.

3 Sep 2008

Actavis launches Ondansetron tablets in the U.S.

Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.

28 Jun 2007

Mylan receives FDA approval for Ondansetron tablets

Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Applications (ANDAs) for Ondansetron Hydrochloride (HCl) Tablets, 4 mg (base), 8 mg (base) and 24 mg (base), and Ondansetron Orally Disintegrating Tablets (ODT) USP, 4 mg and 8 mg.

26 Jun 2007

Acupuncture more effective at reducing nausea and vomiting after major breast surgery than the leading medication

The researchers also found that patients who underwent the 5,000-year-old Chinese practice reported decreased postoperative pain and increased satisfaction with their postoperative recovery. In conducting the trial, the researchers also demonstrated that the pressure point they stimulated possesses previously unknown pain-killing properties.

22 Sep 2004